AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26694646 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress at 36 wk
Number of subjects: 1391
Study 22926460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 24
Study 22926460 — intervention group
Group type: COMPARATOR
Intervention: Chest Physical Therapy (CPT)
Number of subjects: 24
Study 20096799 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg od)
Number of subjects: 21
Study 20096799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20096799 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21
Study 19029420 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Telephone Symptom Management (ATSM) intervention
Number of subjects: 0
Study 19029420 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Nurse‐Administered Symptom Management intervention
Number of subjects: 0
Study 19029420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agents chemotherapy
Number of subjects: 0
Study 19029420 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy protocols
Number of subjects: 0
Study 16497598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch + stimulant medication
Number of subjects: 10
Study 16497598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch only
Number of subjects: 10
Study 16497598 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch + stimulant medication
Number of subjects: 10
Study 16497598 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch only
Number of subjects: 10
Study 16497598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch administration
Number of subjects: 10
Study 16497598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 10
Study 12581463 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate MUFA (MM) diet
Number of subjects: 51
Study 12581463 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA (HM) diet
Number of subjects: 51
Study 12581463 — intervention group
Group type: COMPARATOR
Intervention: Reference (SFA) diet
Number of subjects: 51
Study 10606836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (50, 200 or 400 mg three times daily)
Number of subjects: 412
Study 10606836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 9180124 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise training (2 h of walking daily and four weekly sessions of high intensity monitored stationary cycling for 2 months)
Number of subjects: 25
Study 9180124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 25
Study 1336886 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg epinephrine
Number of subjects: 15
Study 1336886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2992264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin (12 g/day)
Number of subjects: 30
Study 2992264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose (15 g/day)
Number of subjects: 30
Study 2992264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignin (12 g/day)
Number of subjects: 30
Study 29981576 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump stimulation (10 min intermittently for each breast with a negative pressure of 250 mmHg)
Number of subjects: 108
Study 29981576 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin administration (30 IU in 1000 mL of Ringer's serum, max rate of 10 mL/min)
Number of subjects: 108
Study 29981576 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump stimulation
Number of subjects: 108
Study 29981576 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin administration
Number of subjects: 108
Study 28812403 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) once in two weeks
Number of subjects: 123
Study 28812403 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 26612421 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified rice
Number of subjects: 904
Study 26612421 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 904
Study 26612421 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with febrile illness
Number of subjects: 904
Study 24186591 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) at proximal phalanges using DBM Sonic 1200
Number of subjects: 55
Study 24186591 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) at proximal phalanges
Number of subjects: 55
Study 21373936 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering pCO(2) therapy
Number of subjects: 104
Study 21373936 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising pCO(2) therapy
Number of subjects: 104
Study 21373936 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 104
Study 18786749 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding with opioid-sparing analgesia
Number of subjects: 62
Study 18786749 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 62
Study 16644317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT)
Number of subjects: 40
Study 16644317 — intervention group
Group type: COMPARATOR
Intervention: Standard periodontal therapy
Number of subjects: 40
Study 12809583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg once daily (Group 1)
Number of subjects: 37
Study 12809583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 900 mg/twice weekly (Group 2)
Number of subjects: 37
Study 10852265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (initially 100 mg daily, reduced to 50-25 mg daily for maintenance)
Number of subjects: 22
Study 10852265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 22
Study 8856544 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable pins
Number of subjects: 23
Study 8856544 — intervention group
Group type: COMPARATOR
Intervention: Kirschner wires
Number of subjects: 23
Study 1739629 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 400 mg m‐2 alone (Arm A)
Number of subjects: 161
Study 1739629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg m‐2 with chlorambucil 10 mg day‐1 for 7 days (Arm B)
Number of subjects: 161
Study 1739629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 161
Study 6748722 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion solution (1 L delivered just prior to removal of the aortic clamp)
Number of subjects: 112
Study 6748722 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmodified blood reperfusate)
Number of subjects: 112
Study 29572190 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 29572190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27050843 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-step hand hygiene technique
Number of subjects: 120
Study 27050843 — intervention group
Group type: COMPARATOR
Intervention: 3-step hand hygiene technique
Number of subjects: 120
Study 23662599 — intervention group
Group type: EXPERIMENTAL
Intervention: Firocoxib chewable preparation
Number of subjects: 18
Study 23662599 — intervention group
Group type: EXPERIMENTAL
Intervention: Firocoxib equine paste
Number of subjects: 18
Study 23662599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 23088336 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 689
Study 23088336 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg
Number of subjects: 689
Study 23088336 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r)
Number of subjects: 689
Study 23088336 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 689
Study 20561645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (InterStim)
Number of subjects: 33
Study 20561645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 33
Study 20561645 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 33
Study 18212487 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NTX measurements
Number of subjects: 43
Study 18212487 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NTX measurements
Number of subjects: 43
Study 18212487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16391473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (specific drugs not mentioned)
Number of subjects: 0
Study 16391473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0
Study 15288412 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. fentanyl plus low dose i.v. ketamine (group 1)
Number of subjects: 143
Study 15288412 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl (group 2)
Number of subjects: 143
Study 15288412 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl (group 3)
Number of subjects: 143
Study 15288412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative low-dose i.v. ketamine (group 1)
Number of subjects: 143
Study 11407694 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 71
Study 9248867 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 40
Study 9248867 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 40
Study 7969342 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (40 micrograms subcutaneously daily)
Number of subjects: 40
Study 7969342 — intervention group
Group type: COMPARATOR
Intervention: Nafarelin (200 micrograms intranasally twice daily)
Number of subjects: 40
Study 7969342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin plus parathyroid hormone
Number of subjects: 40
Study 3311550 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay‐m‐1099 (50 mg)
Number of subjects: 9
Study 3311550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29112939 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious games platform (Rehab@Home)
Number of subjects: 16
Study 29112939 — intervention group
Group type: COMPARATOR
Intervention: Exergame using the Wii platform
Number of subjects: 16
Study 27060152 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase)
Number of subjects: 42
Study 27060152 — intervention group
Group type: COMPARATOR
Intervention: SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Number of subjects: 42
Study 24452700 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (n = 10)
Number of subjects: 20
Study 24452700 — intervention group
Group type: COMPARATOR
Intervention: Internal focus (n = 10)
Number of subjects: 20
Study 22246378 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and vigorous exercise training for 12 weeks
Number of subjects: 29
Study 20630306 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl solution
Number of subjects: 40
Study 20630306 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl gel
Number of subjects: 40
Study 20630306 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 18362558 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream application
Number of subjects: 44
Study 18362558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15919434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and tacrolimus (TAC)
Number of subjects: 30
Study 15919434 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED) and tacrolimus (TAC)
Number of subjects: 30
Study 12564350 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT)
Number of subjects: 88
Study 12564350 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 88
Study 12564350 — intervention group
Group type: COMPARATOR
Intervention: Friendly Visit (FV)
Number of subjects: 88
Study 10555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (interviewed about attitudes towards pain)
Number of subjects: 26
Study 10555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II attitudes (focusing on pain sensation)
Number of subjects: 26
Study 10555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I attitudes (focusing on disorder)
Number of subjects: 26
Study 8909331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 120 mg/day
Number of subjects: 34
Study 8909331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1907599 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Support Program (CSP)
Number of subjects: 0
Study 1907599 — intervention group
Group type: COMPARATOR
Intervention: Conventional community nursing care
Number of subjects: 0
Study 6683399 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracontact procedures (baby placed on mother's abdomen for 1 hour)
Number of subjects: 59
Study 6683399 — intervention group
Group type: COMPARATOR
Intervention: Routine care procedures (baby shown to mother and then taken to nursery)
Number of subjects: 59
Study 6683399 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracontact procedures
Number of subjects: 59
Study 6683399 — intervention group
Group type: COMPARATOR
Intervention: Both extracontact and routine care procedures
Number of subjects: 59
Study 30855442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential acupoint stimulation
Number of subjects: 0
Study 30855442 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 0
Study 29741592 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE (surgery, antibiotics, facial cleanliness, and environmental improvement) interventions
Number of subjects: 15632
Study 29741592 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydial infection
Number of subjects: 15632
Study 26762729 — intervention group
Group type: EXPERIMENTAL
Intervention: APSES (MiStent)
Number of subjects: 805
Study 26762729 — intervention group
Group type: COMPARATOR
Intervention: EES (Xience)
Number of subjects: 805
Study 25682077 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg daily for 1 week then 1 g twice daily for a further week)
Number of subjects: 0
Study 25682077 — intervention group
Group type: COMPARATOR
Intervention: Control (not receiving metformin)
Number of subjects: 0
Study 22257314 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshest available blood
Number of subjects: 910
Study 22257314 — intervention group
Group type: COMPARATOR
Intervention: Standard-age blood
Number of subjects: 910
Study 20975299 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise bout
Number of subjects: 80
Study 20975299 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of physical training without antioxidants
Number of subjects: 80
Study 20975299 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks of physical training with antioxidants (vitamin C 1,000 mg/day and vitamin E 400 IU/day)
Number of subjects: 80
Study 20975299 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour exercise bout
Number of subjects: 80
Study 20975299 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of training
Number of subjects: 80
Study 18846024 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, single dose)
Number of subjects: 34
Study 18846024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15957827 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound periploca liquid (CPL)
Number of subjects: 81
Study 15957827 — intervention group
Group type: EXPERIMENTAL
Intervention: Periploca syrup
Number of subjects: 81
Study 15957827 — intervention group
Group type: COMPARATOR
Intervention: Youtuoxin (YXG)
Number of subjects: 81
Study 12143978 — intervention group
Group type: EXPERIMENTAL
Intervention: Comminution of the femoral calcar
Number of subjects: 32
Study 12143978 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus displacement in excess of 30 degrees
Number of subjects: 32
Study 12143978 — intervention group
Group type: EXPERIMENTAL
Intervention: Small head fragment
Number of subjects: 32
Study 12143978 — intervention group
Group type: EXPERIMENTAL
Intervention: Garden classification (overall)
Number of subjects: 32
Study 12143978 — intervention group
Group type: EXPERIMENTAL
Intervention: Garden classification (divided into Garden 1‐2 and 3‐4)
Number of subjects: 32
Study 12143978 — intervention group
Group type: EXPERIMENTAL
Intervention: Displaced vs. undisplaced classification
Number of subjects: 32
Study 10513491 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week weight-bearing physical conditioning program
Number of subjects: 25
Study 10513491 — intervention group
Group type: COMPARATOR
Intervention: Control period (8 weeks before exercise)
Number of subjects: 25
Study 7781839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Expert
Number of subjects: 155
Study 2031815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg kg‐1 with previous suxamethonium 1 mg kg‐1
Number of subjects: 18
Study 2031815 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.2 mg kg‐1 without previous suxamethonium
Number of subjects: 18
Study 6382991 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 240 mg twice a day)
Number of subjects: 19
Study 6382991 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (120 to 240 mg twice a day)
Number of subjects: 19
Study 30202883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuse Solo (VS) Digital Vapor Cigarettes
Number of subjects: 153
Study 30202883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorette 4 mg nicotine gum (NG)
Number of subjects: 153
Study 30202883 — intervention group
Group type: COMPARATOR
Intervention: Combustible cigarettes (CCs)
Number of subjects: 153
Study 29449034 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural activities
Number of subjects: 11
Study 29449034 — intervention group
Group type: COMPARATOR
Intervention: Occupational activities
Number of subjects: 11
Study 27549415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 136
Study 27549415 — intervention group
Group type: COMPARATOR
Intervention: Transcervical Foley catheter plus oxytocin
Number of subjects: 136
Study 27549415 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity and higher Bishop's score
Number of subjects: 136
Study 24727719 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure comedy sketch
Number of subjects: 0
Study 24727719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondisclosure comedy sketch
Number of subjects: 0
Study 24727719 — intervention group
Group type: COMPARATOR
Intervention: Control comedy sketch
Number of subjects: 0
Study 22871173 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, physical exercise and cognitive behavioral training during working hours 1 hour/week
Number of subjects: 98
Study 22871173 — intervention group
Group type: COMPARATOR
Intervention: Monthly oral presentations
Number of subjects: 98
Study 20678689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl 0.05 mg/0.1 mL
Number of subjects: 36
Study 20678689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (preserved normal saline) 0.1 mL
Number of subjects: 36
Study 20805137 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT) in addition to conventional medical therapy
Number of subjects: 100
Study 20805137 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy alone
Number of subjects: 100
Study 16193890 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral methylprednisolone
Number of subjects: 50
Study 16193890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11890187 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day mianserin (n = 9)
Number of subjects: 18
Study 11890187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 18
Study 9716143 — intervention group
Group type: EXPERIMENTAL
Intervention: CTEPH patients
Number of subjects: 140
Study 9716143 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH patients
Number of subjects: 140
Study 9716143 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 140
Study 7913907 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 70
Study 7913907 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 70
Study 3054651 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin
Number of subjects: 209
Study 3054651 — intervention group
Group type: COMPARATOR
Intervention: Triple-dose cefoxitin
Number of subjects: 209
Study 29795314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue antenatal steroids (ideal treatment)
Number of subjects: 56
Study 29795314 — intervention group
Group type: COMPARATOR
Intervention: Rescue antenatal steroids (remote treatment)
Number of subjects: 56
Study 27059830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulus applied for 2 minutes before and after meals for 5 days.
Number of subjects: 16
Study 27059830 — intervention group
Group type: COMPARATOR
Intervention: Nonvibratory controls (no vibratory stimulus applied).
Number of subjects: 16
Study 25582493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² and pemetrexed 500 mg/m², every 3 weeks for 6 cycles followed by maintenance pemetrexed
Number of subjects: 118
Study 25582493 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin AUC 6, paclitaxel 200 mg/m², and bevacizumab 15 mg/kg, every 3 weeks for 6 cycles followed by maintenance bevacizumab
Number of subjects: 118
Study 24300198 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized out-of-hospital management, regular health education, and follow-ups via telephone and outpatient visits.
Number of subjects: 734